Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

967 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systemic diffuse large B-cell lymphoma involving the central nervous system has high rates of defective antigen presentation and immune surveillance.
Wight J, Blombery P, Lickiss J, Burgess M, Gould C, Minson A, Swain F, Sabdia MB, Gandhi MK, Birchley A, Keane C, Hawkes EA. Wight J, et al. Among authors: burgess m. Haematologica. 2024 Sep 1;109(9):3013-3018. doi: 10.3324/haematol.2023.284600. Haematologica. 2024. PMID: 38511272 Free PMC article. No abstract available.
Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.
Manos K, Chong G, Keane C, Lee ST, Smith C, Churilov L, McKendrick J, Renwick W, Blombery P, Burgess M, Nelson NE, Fancourt T, Hawking J, Lin W, Scott AM, Barraclough A, Wight J, Grigg A, Fong CY, Hawkes EA. Manos K, et al. Among authors: burgess m. Leukemia. 2023 May;37(5):1092-1102. doi: 10.1038/s41375-023-01863-7. Epub 2023 Mar 11. Leukemia. 2023. PMID: 36906715 Clinical Trial.
Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.
Gunawardana J, Law SC, Sabdia MB, Fennell É, Hennessy A, Leahy CI, Murray PG, Bednarska K, Brosda S, Trotman J, Berkahn L, Zaharia A, Birch S, Burgess M, Talaulikar D, Lee JN, Jude E, Hawkes EA, Jain S, Nath K, Snell C, Swain F, Tobin JWD, Keane C, Shanavas M, Blyth E, Steidl C, Savage K, Farinha P, Boyle M, Meissner B, Green MR, Vega F, Gandhi MK. Gunawardana J, et al. Among authors: burgess m. Am J Hematol. 2024 Nov;99(11):2096-2107. doi: 10.1002/ajh.27459. Epub 2024 Aug 17. Am J Hematol. 2024. PMID: 39152767
Research data use in a digital society: a deliberative public engagement.
McGrail KM, Teng J, Bentley C, O'Doherty KC, Burgess MM. McGrail KM, et al. Among authors: burgess mm. Int J Popul Data Sci. 2024 Oct 14;9(1):2372. doi: 10.23889/ijpds.v9i1.2372. eCollection 2024. Int J Popul Data Sci. 2024. PMID: 39620125 Free PMC article.
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.
Mowery YM, Ballman KV, Hong AM, Schuetze SM, Wagner AJ, Monga V, Heise RS, Attia S, Choy E, Burgess MA, Bae S, Pryor DI, Van Tine BA, Tinoco G, Chmielowski B, Freeman C, Gronchi A, Meyer CF, Dickson MA, Hartner L, Davis LE, Powers BC, Moding EJ, Weinhold KJ, van de Rijn M, Brigman BE, Riedel RF, Kirsch DG. Mowery YM, et al. Among authors: burgess ma. Lancet. 2024 Nov 23;404(10467):2053-2064. doi: 10.1016/S0140-6736(24)01812-9. Epub 2024 Nov 12. Lancet. 2024. PMID: 39547252 Clinical Trial.
967 results